HOW CONTROVERSIAL ARE SURROGATE END-POINTS

被引：4

|

作者：

MAMELOK, R

机构：

来源：

BIO-TECHNOLOGY | 1994年 / 12卷 / 02期

关键词：

D O I：

10.1038/nbt0294-134

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

收藏

页码：134 / 135

页数：2

相关论文

共 50 条

[31] POINTS AND END-POINTS IN PEDIATRIC ONCOLOGY
DANGIO, GJ
MEDICAL AND PEDIATRIC ONCOLOGY, 1992, 20 (01): : 1 - 5
[32] Biomarkers of myocardial injury as surrogate end-points for remote ischemic conditioning trials
Iliodromitis, Efstathios K.
Farmakis, Dimitrios
Kremastinos, Dimitrios T.
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 149 (03) : 379 - 379
[33] A CHECKLIST FOR SUITABILITY OF BIOMARKERS AS SURROGATE END-POINTS IN CHEMOPREVENTION OF BREAST-CANCER
BOGOCH, S
BOGOCH, ES
JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 173 - 185
[34] Ocular Defects as Surrogate End-Points in Trials Comparing Carotid Endarterectomy and Stenting
Giannoukas, A. D.
Paraskevas, K. I.
Bulbulia, R.
Halliday, A.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2014, 48 (01) : 105 - 106
[35] SURROGATE END-POINTS IN CHEMOPREVENTION OF BREAST-CANCER - GUIDELINES FOR EVALUATION OF NEW BIOMARKERS
HILSENBECK, SG
CLARK, GM
JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 205 - 211
[36] BIOLOGICAL SIGNIFICANCE OF END-POINTS
DUNKEL, VC
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1983, 407 (JUN) : 34 - 41
[37] Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome?
Legro, RS
Myers, E
HUMAN REPRODUCTION, 2004, 19 (08) : 1697 - 1704
[38] Mutagenicity and related end-points
Environmental Health Criteria, 1990, (107):
[39] SETS OF END-POINTS AND RAMIFICATION POINTS IN DENDROIDS
NIKIEL, J
TYMCHATYN, ED
FUNDAMENTA MATHEMATICAE, 1991, 138 (02) : 139 - 146
[40] Surrogate end points: how well do they represent patient-relevant end points?
Jost, Marco M.
BIOMARKERS IN MEDICINE, 2007, 1 (03) : 437 - 451

← 1 2 3 4 5 →